Squarepoint Ops LLC Sells 36,055 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK)

Squarepoint Ops LLC reduced its position in Stoke Therapeutics, Inc. (NASDAQ:STOK) by 70.6% during the second quarter, Holdings Channel.com reports. The institutional investor owned 15,042 shares of the company’s stock after selling 36,055 shares during the period. Squarepoint Ops LLC’s holdings in Stoke Therapeutics were worth $203,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in STOK. Quest Partners LLC bought a new stake in Stoke Therapeutics in the 2nd quarter worth approximately $29,000. Nisa Investment Advisors LLC grew its holdings in shares of Stoke Therapeutics by 53.2% in the second quarter. Nisa Investment Advisors LLC now owns 2,989 shares of the company’s stock valued at $40,000 after purchasing an additional 1,038 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in shares of Stoke Therapeutics in the second quarter valued at $123,000. State Board of Administration of Florida Retirement System bought a new stake in Stoke Therapeutics in the first quarter worth $141,000. Finally, BNP Paribas Financial Markets raised its stake in Stoke Therapeutics by 86.2% during the first quarter. BNP Paribas Financial Markets now owns 14,330 shares of the company’s stock valued at $193,000 after purchasing an additional 6,636 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on STOK shares. HC Wainwright reissued a “buy” rating and issued a $35.00 price objective on shares of Stoke Therapeutics in a research note on Wednesday, September 11th. Needham & Company LLC reissued a “buy” rating and set a $22.00 price objective on shares of Stoke Therapeutics in a research note on Thursday, August 8th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $17.00 price objective on shares of Stoke Therapeutics in a research note on Thursday, July 11th. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $21.40.

Insider Buying and Selling at Stoke Therapeutics

In other news, major shareholder Skorpios Trust sold 1,937,500 shares of Stoke Therapeutics stock in a transaction on Thursday, September 19th. The stock was sold at an average price of $14.05, for a total transaction of $27,221,875.00. Following the completion of the sale, the insider now directly owns 8,906,181 shares in the company, valued at approximately $125,131,843.05. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 11.30% of the stock is currently owned by corporate insiders.

Stoke Therapeutics Trading Up 3.9 %

Shares of NASDAQ:STOK opened at $11.84 on Friday. Stoke Therapeutics, Inc. has a 12 month low of $3.35 and a 12 month high of $17.58. The company has a market capitalization of $623.38 million, a price-to-earnings ratio of -5.43 and a beta of 0.97. The firm’s 50-day moving average is $13.79 and its 200 day moving average is $13.72.

Stoke Therapeutics (NASDAQ:STOK) last released its earnings results on Wednesday, August 7th. The company reported ($0.46) EPS for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.11. Stoke Therapeutics had a negative return on equity of 57.89% and a negative net margin of 683.35%. The firm had revenue of $4.83 million for the quarter, compared to analysts’ expectations of $3.33 million. As a group, equities analysts forecast that Stoke Therapeutics, Inc. will post -2.1 EPS for the current fiscal year.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.